Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announced that its clinical facility in Mexico City has begun recruiting patients for Group Two of its ongoing human clinical study of the Ocumetics Lens, a next-generation accommodating intraocular lens. This move follows encouraging results from Group One, which focused solely on safety, and represents a pivotal expansion of the trial to assess both safety and visual performance.
The Group Two study will evaluate the lens for safety, distance vision, and near vision, with surgeries planned for fall 2026. Patients enrolled in this phase will receive the latest-generation Ocumetics Lens, which incorporates design advancements and will be delivered using an enhanced delivery system. This progression underscores the company's commitment to refining its technology and moving toward a product that could potentially eliminate the need for glasses or contact lenses.
Dean Burns, President and CEO of Ocumetics, expressed enthusiasm about the milestone, stating, "We are extremely excited to begin the process of moving into our larger Group Two study. Commencement of this study represents another important milestone in the continued clinical development of the Ocumetics Lens. Recruiting will be completed soon and we will schedule surgical dates shortly thereafter."
The initiation of Group Two comes as Group One patients approach their 12-month follow-up visits, which will provide longer-term clinical data on the lens's safety and performance. The company noted that Group One outcomes "met and exceeded" expectations regarding safety, performance, and handling, providing valuable insights for the trial's progression.
"We are particularly excited to reach the 12-month milestone for our Group One patients, which will provide an important body of longer-term clinical data as we continue to advance the Ocumetics Lens," said Burns. "At the same time, the Group Two study represents an important step forward as we introduce our next-generation Ocumetics Lens together with our next-generation lens delivery system. This combination represents the continued evolution of our technology and our commitment to developing a truly differentiated solution for patients seeking improved vision across a broader range of distances."
The Ocumetics Lens is designed to fit within the eye's natural lens compartment and utilizes the eye's natural muscle activity to shift focus between distances, potentially providing clear vision at all ranges without perceptible time lag. If successful, this technology could offer a transformative alternative to current vision correction methods, addressing a significant unmet need in ophthalmology.
The clinical development of the Ocumetics Lens is being closely watched by the ophthalmic community, as current accommodating intraocular lenses have limitations in restoring full range of vision. The company's next-generation design aims to overcome these challenges, and the Group Two study will be critical in determining whether the lens delivers on its promise.
As the trial progresses, the outcomes will not only inform the future of Ocumetics but could also reshape the standard of care for cataract surgery and refractive lens exchange. With an aging global population and increasing demand for vision correction, innovations like the Ocumetics Lens have the potential to significantly improve quality of life for millions.
Ocumetics Technology Corp. is a Canadian research and product development company focused on advanced vision correction solutions. The company is currently in the first-in-human early feasibility study phase of its dynamic intraocular lens technology.
